Pharmaceutical

Risk adjusted net present value: What is the current valuation of Pfizer’s Osivelotor?

Osivelotor is a small molecule commercialized by Pfizer, with a leading Phase III program in Sickle Cell Disease.

Jul 2, 2024 - 04:00
Osivelotor is a small molecule commercialized by Pfizer, with a leading Phase III program in Sickle Cell Disease.
Read the original article

Tags:

Previous Article

Risk adjusted net present value: What is the current valuation of PMV Pharmaceut...

Next Article

Risk adjusted net present value: What is the current valuation of Pfizer’s Idreb...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Innate shelves lacutamab monotherapy plans in peripheral T cell lymphoma

Innate shelves lacutamab monotherapy plans in periphera...

Mar 24, 2024

STAT+: Shareholders elect director’s romantic partner to Biogen’s board

STAT+: Shareholders elect director’s romantic partner t...

Jun 26, 2023

STAT+: More drugmakers are filing continuation patents that sideline generic competition

STAT+: More drugmakers are filing continuation patents ...

Aug 9, 2023